Roivant Sciences ROIV
NASDAQ ROIV
$35.01 +0.60 (+1.74%)
As of: Sep 4, 2026 · 2:30 PM EDT

Roivant Sciences (ROIV) Income from Continuing Operations (2020 - 2026)

Roivant Sciences' (ROIV) quarterly Income from Continuing Operations came in at 753651000.0 in Q4 2025, down 66.38% YoY from 2241716427.54 in Q4 2024, and down 353.9% on a QoQ basis from 166039000.0 in Q3 2025.

Analysis

Roivant Sciences (ROIV) Income from Continuing Operations (2020 - 2026) Analysis & Trends

Roivant Sciences (ROIV) has 6 years of Income from Continuing Operations data on file, last reported at 753651000.0 in Q4 2025.

  • Quarterly Income from Continuing Operations fell 66.38% year-over-year to 753651000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1646569000.0 (down 137.38% YoY) and the FY2026 annual result came in at 397907000.0, up 45.47% from the prior year.
  • Income from Continuing Operations fell to 753651000.0 in Q4 2025, from 166039000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5126269000.0 in Q4 2023 to a low of 1054601000.0 in Q4 2022.
  • A 5-year average of 3003866.67 and a median of 273911000.0 in 2025 frame the typical range for Income from Continuing Operations.
  • Annual changes were most pronounced in 2021 — Income from Continuing Operations tumbled 1167.12% — and 2023, when it soared 586.09%.
  • Tracing ROIV's Income from Continuing Operations over 5 years: stood at 632803000.0 in 2021, then tumbled by 66.66% to 1054601000.0 in 2022, then soared by 586.09% to 5126269000.0 in 2023, then plunged by 108.84% to 452968000.0 in 2024, then sank by 66.38% to 753651000.0 in 2025.
  • The last three Income from Continuing Operations figures came in at 753651000.0 (Q4 2025), 166039000.0 (Q3 2025), and 273911000.0 (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 138.78 Bn 130.92 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.50 Bn 77.51 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.06 Bn 52.92 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn - -644.37 Mn
6 BeOne Medicines 40.04 Bn 34.94 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn - 81.49 Mn
9 Insmed 27.42 Bn 26.26 Bn 358.27 Mn -13.27 Mn
10 Roivant Sciences 25.22 Bn 25.22 Bn 1.16 Mn -290.61 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -290.61 Mn
Dec 31, 2025 -753.65 Mn
Sep 30, 2025 -166.04 Mn
Jun 30, 2025 -273.91 Mn
Dec 31, 2024 -452.97 Mn
Sep 30, 2024 -236.84 Mn
Jun 30, 2024 -31.60 Mn
Dec 31, 2023 5.13 Bn
Sep 30, 2023 -244.64 Mn
Jun 30, 2023 -327.85 Mn
Dec 31, 2022 -1.05 Bn
Sep 30, 2022 -315.92 Mn
Jun 30, 2022 -353.78 Mn
Dec 31, 2021 -632.80 Mn
Sep 30, 2021 -225.64 Mn
Jun 30, 2021 -101.08 Mn
Dec 31, 2020 -275.60 Mn
Sep 30, 2020 -53.50 Mn
Jun 30, 2020 -7.98 Mn